Polyphenol rich botanicals used as food supplements interfere with EphA2-ephrinA1 system

Pharmacological Research

Volumn 64, Issue 5, 2011, Pages 464-470

  Mohamed, Iftiin Hassan ^a   Giorgio, Carmine ^a   Bruni, Renato ^a   Flammini, Lisa ^a   Barocelli, Elisabetta ^a   Rossi, Damiano ^b   Domenichini, Giuseppe ^a   Poli, Ferruccio ^c   Tognolini, Massimiliano ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cancer; Dietary phytochemicals; Eph kinases; Ephrin; Herbal supplements; Screening

Indexed keywords

ANTINEOPLASTIC AGENT; ARCTOSTAPHYLOS UVA URSI EXTRACT; AZADIRACHTA INDICA EXTRACT; DASATINIB; EMBELIA RIBES EXTRACT; EMBLICA OFFICINALIS EXTRACT; EPHRIN RECEPTOR A1; EPHRIN RECEPTOR A2; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESSENTIAL OIL; GINKGO BILOBA EXTRACT; LAGERSTROEMIA SPECIOSA EXTRACT; PLANT EXTRACT; POLYPHENOL; POMEGRANATE EXTRACT; TERMINALIA BELLIRICA EXTRACT; TERMINALIA CHEBULA EXTRACT; UNCLASSIFIED DRUG;

ARCTOSTAPHYLOS UVA URSI; ARTICLE; AZADIRACHTA INDICA; BINDING ASSAY; CARCINOMA CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; EMBELIA RIBES; EMBLICA OFFICINALIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GINKGO BILOBA; HUMAN; HUMAN CELL; IC 50; LAGERSTROEMIA; LAGERSTROEMIA SPECIOSA; MALE; MODULATION; PHYTOCHEMISTRY; POMEGRANATE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN PHOSPHORYLATION; SCREENING; TERMINALIA BELLIRICA; TERMINALIA CHEBULA;

EID: 80054998744     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2011.06.008     Document Type: Article

References (47)

1. Riboli E, Norat T. Epidemiologic evidence of the protective effect of fruit and vegetables on cancer risk. Am J Clin Nutr 2003;78:559S-69S.
2. Pavia M, Pileggi C, Nobile CG, Angelillo IF. Association between fruit and vegetable consumption and oral cancer: a meta-analysis of observational studies. Am J Clin Nutr 2006;83:1126-34. (Pubitemid 44713114)
3. Whu AH, Yu MC, Tseng CC, Pike MC. Epidemiology of soy exposures and breast cancer risk. Brit J Cancer 2008;98:9-14.
4. Sofi F, Cesari F, Abbate R, Gensini GF, Casini A. Adherence to mediterranean diet and health status: meta-analysis. Brit Med J 2008;337:344-51.
5. Myung SK, Kim Y, Ju W, Choi HJ, Bae WK. Effects of antioxidant supplements on cancer prevention: meta-analysis of randomized controlled trials. Ann Oncol 2009;21:166-79.
6. Bardia A, Platz EA, Yegnasubramanian S, De Marzo AM, Nelson WG. Antiinflammatory drugs, antioxidants, and prostate cancer prevention. Curr Opin Pharmacol 2009;9:419-26.
7. Bardia A, Tleyjeh IM, Cerhan JR, Sood AK, Limburg PJ, Erwin PJ, Montori VM. Efficacy of antioxidant supplementation in reducing primary cancer incidence and mortality: systematic review and meta-analysis. Mayo Clin Proc 2008;83:23-34.
8. Mekary RA, Wu K, Giovannucci E, Sampson L, Fuchs C, Spiegelman D, et al. Total antioxidant capacity intake and colorectal cancer risk in the Health Professionals Follow-up Study. Cancer Causes Contr 2010;21:1315-21.
9. Liu RH. Potential synergy of phytochemicals in cancer prevention: mechanism of action. J Nutr 2004;134:3479S-85S.
10. Stan SD, Kar S, Stoner GD, Singh SV. Bioactive food components and cancer risk reduction. J Cell Biochem 2008;104:339-56.
11. Surawska H, Ma PC, Salgia R. The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev 2004;15:419-33. (Pubitemid 39550453)
12. Gale NW, Yancopoulos GD. Ephrins and their receptors: a repulsive topic? Cell Tiss Res 1997;290:227-41. (Pubitemid 27470055)
13. Hafner C, Schmitz G, Meyer S, Bataille F, Haum P, Langmann T, et al. Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem 2004;50:490-9. (Pubitemid 38297297)
14. Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, Pasquale EB. The ephrin-A1 ligand and its receptor EphA2, are expressed during tumor neovascularization. Oncogene 2000;19:6043-52. (Pubitemid 32039378)
15. Walker-Daniels J, Hess AR, Hendrix MJ, Kinch MS. Differential regulation of EphA2 in normal and malignant cells. Am J Pathol 2003;162:1037-42. (Pubitemid 36350648)
16. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 2001;61:2301-6. (Pubitemid 32692063)
17. Sugimura H, Wang JD, Mori H, Tsuboi M, Nagura K, Igarashi H, et al. Eph-ephrin in human gastrointestinal cancers. World J Gastrointest Oncol 2010;2:421-8.
18. Wykosky J, Debinski W. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res 2008;6:1795-806.
19. Cheng N, Brantley DM, Liu H, Lin Q, Enriquez M, Gale N, et al. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res 2002;1:2-11. (Pubitemid 36330206)
20. Fang WB, Brantley-Sieders DM, Parker MA, Reith AD, Chen J. A kinasedependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene 2005;24:7859-68. (Pubitemid 41715192)
21. Brantley DM, Cheng N, Thompson EJ, Lin Q, Brekken RA, Thorpe PE, et al. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 2002;21:7011-26. (Pubitemid 35252975)
22. Carles-Kinch K, Kilpatrick KE, Stewart JC, Kinch MS. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res 2002;62:2840-7. (Pubitemid 34525769)
23. Dobrzanski P, Hunter K, Jones-Bolin S, Chang H, Robinson C, Pritchard S, et al. Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res 2004;64:910-9. (Pubitemid 38176892)
24. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 2010;10:165-80.
25. Kosinski C, Li VS, Chan AS, Zhang J, Ho C, Tsui WY, et al. Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors. Proc Natl Acad Sci USA 2007;104:15418-23. (Pubitemid 47502932)
26. Moore KA, Lemischka R. Stem cells and their niches. Science 2006;31:1880-5.
27. Toth J, Cutforth T, Gelinas AD, Bethoney KA, Bard J, Harrison CJ. Crystal structure of an ephrin ectodomain. Dev Cell 2001:83-92. (Pubitemid 33586071)
28. Tang FY, Chiang EP, Shih CJ. Green tea catechin inhibits ephrin-A1-mediated cell migration and angiogenesis of human umbilical vein endothelial cells. J Nutr Biochem 2007;18:391-9.
29. Chaovanalikit A, Wrolstad RE. Total antocyanins and total phenolics of fresh and processed cherries and their antioxidant properties. Food Chem Toxicol 2004;69:67-72.
30. Porter LJ, Hrstich LN, Chan BC. The conversion of procyanidins and prodelphinidins to cyanidins and delphinidins. Phytochemistry 1986;25:225-30.
31. Luximon-Ramma A, Bahorun T, Soobrattee MA, Aruoma OI. Antioxidant activities of phenolic, proanthocyanidin, and flavonoid components in extracts of Cassia fistula. J Agric Food Chem 2002;50:5042-7. (Pubitemid 34925088)
32. Giorgio C, Hassan Mohamed I, Flammini L, Barocelli E, Incerti M, Lodola A, et al. Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation. PLoS One 2011;6:e18128.
33. Miao H, Burnett E, Kinch M, Simon E, Wang B. Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat Cell Biol 2000;2:62-9.
34. Tanaka M, Kamata R, Sakai R. EphA2 phosphorylates the cytoplasmic tail of claudin-4 and mediates paracellular permeability. J Biol Chem 2005;280:42375-82. (Pubitemid 43023209)
35. Chang Q, Jorgensen C, Pawson T, Hedley DW. Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. Brit J Cancer 2008;99:1074-82.
36. Sah JF, Balasubramanian S, Eckert RL, Rorke EA. Epigallocatechin-3- gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases. J Biol Chem 2006;279: 12755-62.
37. Aggarwal BB, Ichikawa H, Garodia P, Weerasinghe P, Sethi G, Bhatt ID, et al. From traditional ayurvedic medicine to modern medicine: identification of therapeutic targets for suppression of inflammation and cancer. Expert Opin Ther Targets 2006;10:87-118. (Pubitemid 43263269)
38. Balachandran P, Govindarajan R. Cancer - an ayurvedic perspective. Pharm Res 2005;51:19-30. (Pubitemid 39425069)
39. Menon LG, Kuttan R, Kuttan G. Effect of rasayanas in the inhibition of lung metastasis induced by B16F-10 melanoma cells. J Exp Clin Canc Res 1997;16:365-8. (Pubitemid 28083534)
40. Baliga MS. Triphala, ayurvedic formulation for treating and preventing cancer: a review. J Altern Complement Med 2010;16:1301-8.
41. Vimal KP, Wang J, Shen RN, Sharma HM, Brahmi Z. Reduction of metastases of Lewis lung carcinoma by an ayurvedic food supplement in mice. Nutr Res 1992;12:51-61.
42. Lansky EP, Newman RA. Punica granatum (pomegranate) and its potential for prevention and treatment of inflammation and cancer. J Ethnopharmacol 2007;109:177-206. (Pubitemid 44959707)
43. DeFeudis FV, Papadopoulos V, Drieu K. Ginkgo biloba extracts and cancer: a research area in its infancy. Fund Clin Pharm 2003;17: 405-17. (Pubitemid 36920641)
44. Kumar S, Sureah PK, Vijayababu MR, Arunkumar A, Arunakaran J. Anticancer effects of ethanolic neem leaf extract on prostate cancer cell line (PC-3). J Ethnopharmacol 2005;105:246-50.
45. Cortina C, Palomo-Ponce S, Iglesias M, Fernandez-Masip JL, Vivancos A, Whissell G, et al. EphB-ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells. Nat Genet 2007;11:1376-83. (Pubitemid 350034995)
46. Batlle E, Henderson JT, Beghtel H, van den Born MMW, Sancho E, Hols GH, et al. β-Catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 2002;11:251-63. (Pubitemid 35292445)
47. Michels KB, Giovannucci E, Chan AT, Singhania R, Fuchs CS, Willett WC. Fruit and vegetable consumption and colorectal adenomas in the Nurses' Health Study. Cancer Res 2006;66:3942-53.